Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.

We analyzed cytogenetic data at diagnosis in 395 primary myelofibrosis (PMF) patients to evaluate any possible association between karyotype and WHO 2017 classification and its impact on prognosis. All the cases were diagnosed and followed at five Italian Hematological Centers between November 1983 and December 2016. An abnormal karyotype (AK) was found in 69 patients and clustered differently according to bone marrow fibrosis grade as it was found in 31 (27.0%) cases with overt fibrotic and 38 (13.6%) with pre-fibrotic PMF (p = 0.001). Sex, anemia, thrombocytopenia, circulating blasts ≥1%, higher lactate dehydrogenase, and International Prognostic Scoring System risk classes were all significantly associated with karyotype. At a median follow-up of >6 years, 101 deaths were recorded. Survival was different between AK and normal karyotype (NK) patients with an estimated median overall survival (OS) of 11.6 and 25.7 years, respectively (p = 0.0148). In conclusion, in our cohort around 20% of patients had an AK, more frequently in subjects with an advanced bone marrow fibrosis grade and clinical-laboratory features indicative of a more aggressive disease. This study shows that an AK confers a more severe clinical phenotype and impacts adversely on OS, thus representing an additional parameter to be considered in the evaluation of PMF prognosis. © 2020 John Wiley & Sons Ltd.

Citation

Alessandra Iurlo, Francesca Palandri, Elena Maria Elli, Daniele Cattaneo, Cristina Bucelli, Mariarita Sciumè, Donatella Vincelli, Filippo Brioschi, Giuseppe Auteri, Giorgio Alberto Croci, Silvana Guerneri, Giuseppe Isimbaldi, Elena Sabattini, Ivan Cortinovis, Anna Bossi, Vittorio Rosti, Bruno Martino, Luca Baldini, Umberto Gianelli. Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series. Hematological oncology. 2021 Feb;39(1):123-128

Mesh Tags

PMID: 32979286

search → result